ASPHF.US Ascentage Pharma Group International

Healthcare Biotechnology USA Stocks
3.46 USD
Close of Nov 14, 2026
3.46 9.32
Market cap
USD 1.29B
P/E
-
P/B
15.50x
ROE
-579.1%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ASPHF.US undervalued?

Graham number

The Graham number of Ascentage Pharma Group International cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ascentage Pharma Group International fundamental analysis

No fundamental analysis for Ascentage Pharma Group International yet.

Ascentage Pharma Group International stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ascentage Pharma Group International

Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-ABL inhibitor targeting BCR-ABL1 mutants, including those with the T315I mutation. It also develops APG-2575, an oral administered Bcl-2 selective inhibitor for hematologic malignancies and solid tumors; APG-115, an oral small molecul…

Full company profile